StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Positive trial data and rising targets suggest upside potential, especially if Phase 2b timing remains on track; however, the stock is currently oversold and subject to biotech risk, so moves may be volatile.
What happened, with direct paths to the underlying reporting
Shattuck Labs reported positive Phase 1 data for SL-325, a DR3-targeting antibody for inflammatory bowel disease, with favorable safety and occupancy supporting a Phase 2b in 3Q2026. The stock trades near $4.86 with an RSI of 24.1, indicating oversold conditions and potential near-term rebound if data translate into clinical progress. Analysts have raised price targets, signaling longer-term upside.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.